ASO Visual Abstract: Clinical Outcome of Patients Managed with Low-Dose Cisplatin and Doxorubicin delivered as Pressurized Intraperitoneal Aerosol Chemotherapy for Unresectable Peritoneal Metastases of Gastric Cancer

Sindayigaya, Rémy; Dogan, Can; Demtröder, C.; Fischer, Britta; Karam, Elias; Buggisch, Jonathan R.; Tempfer, Clemens; Lecomte, Thierry; Ouaïssi, Mehdi; Giger‐Pabst, Urs

doi:10.1245/s10434-021-10889-z

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported median OS was 11.5 months from the time of PM diagnosis, while the Lyon group recently published OS rates of up to 19.1 months [37, 38]. Repetitive PIPACs, specifically 3 or more, with low-dose cisplatin/doxorubicin is an independent prognostic factor for prolonged OS (from 9 to 16 months) according to Sindayigaya et al [39].…”

Section: Pipac For Upper Gi Cancermentioning

confidence: 99%

Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis?

et al. 2022

View full text Add to dashboard Cite

Background: The survival prognosis of patients with peritoneal metastasis (PM) of gastrointestinal (GI) cancer is generally poor and treatment consists of, according to international guidelines, systemic chemotherapy. A multimodal treatment approach, including cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy, not only proved to be beneficial mainly in colorectal cancer, but also in selected patients with gastric cancer. The authors performed systematic research of articles and ongoing clinical trials using the keywords “PIPAC” and “gastric cancer” or “colorectal cancer” in PubMed in October 2021. Key findings, such as complications rates, treatment protocols, and overall survival were summarized and illustrated in Tables and critically discussed. Summary: Twenty years ago, the technique of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) was developed by Reymond et al. and delivered evidence to be recognized as a basic therapeutic tool in this multimodal therapy. Currently, there are several ongoing Phase II and III trials exploring the usage and efficacy of PIPAC as a neoadjuvant, adjuvant, or palliative component of treatment in patients with PM of GI cancer. Key Messages: The aim of this narrative review was to help navigate the reader throughout the most current evidence for the use PIPAC and to highlight its indication in patients with upper and lower GI cancer with PM. It also provides an outline of ongoing studies and future perspectives.

show abstract

Section: Pipac For Upper Gi Cancermentioning

confidence: 99%